Filing Flows › AbCellera Biologics (ABCL) › Q1 2026 › vs Q4 2025
AbCellera Biologics (ABCL) Q1 2026 vs Q4 2025 (quarter over quarter)
AbCellera Biologics's revenue fell $36.5M (-81%) from $44.9M in Q4 2025 to $8.3M in Q1 2026.
AbCellera Biologics, Q1 2026: revenue $8.3M (+96% year over year), operating margin -691.7%, net loss $43.2M, operating cash flow −$33.5M. The chart draws each line against Q4 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $8.3M | $44.9M | −$36.5M | -81% |
| Other income, net | $8.0M | $9.1M | −$1.1M | -12% |
| Income tax benefit | $6.4M | $10.6M | −$4.2M | -40% |
| Net loss | $43.2M | $8.9M | $34.2M | +383% |
| Costs & expenses | $65.8M | $73.4M | −$7.6M | -10% |
| Operating costs | $65.8M | $73.4M | −$7.6M | -10% |
| Operating cash sources | $52.4M | $53.7M | −$1.4M | -3% |
| Depreciation & amortization | $6.8M | $6.1M | $747K | +12% |
| Share-based compensation | $12.0M | $12.9M | −$891K | -7% |
| Cash used in operations | $33.5M | $34.7M | −$1.2M | -4% |
| Net loss absorbed | $43.2M | $8.9M | $34.2M | +383% |
| Working capital & other | $9.2M | $44.8M | −$35.6M | -79% |
Questions
How much did AbCellera Biologics's revenue grow quarter over quarter in Q1 2026?
AbCellera Biologics's revenue fell $36.5M (-81%) from $44.9M in Q4 2025 to $8.3M in Q1 2026.